We are a privately-held clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases
Our lead program is AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Our initial clinical focus is eosinophilic gastritis, an inflammatory disease of the gastrointestinal tract. We are also conducting clinical trials for other mast cell and eosinophil-driven diseases.